Most recently reported pay: €4.7M. No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
Sep 21, 2026https://www.marketbeat.com/instant-alerts/event-recursion-pharmaceuticals-highlights-ai-drug-platform-fap-progress-at-morgan-stanley-conference-2026-09-20/sentiment +0.30
Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive
Sep 16, 2026https://seekingalpha.com/article/4946915-sanofi-stronger-launches-and-a-new-r-and-d-reset-keep-the-re-rating-case-alivesentiment +0.80
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
Sep 15, 2026https://www.marketbeat.com/instant-alerts/event-vaxart-highlights-oral-vaccine-platform-covid-trial-progress-at-hc-wainwright-conference-2026-09-15/sentiment +0.10
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
Sep 12, 2026https://www.marketbeat.com/instant-alerts/event-regeneron-eyes-2026-catalysts-as-eylea-hd-and-dupixent-drive-growth-2026-09-12/sentiment +0.30
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference
Sep 10, 2026https://www.marketbeat.com/instant-alerts/event-novavax-highlights-matrix-m-licensing-push-oncology-ambitions-at-cantor-conference-2026-09-10/sentiment +0.40
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Aug 25, 2026https://seekingalpha.com/article/4939821-dianthus-therapeutics-stock-c1-shakeout-strengthens-bull-casesentiment -0.40
